Cargando…

Impact of SARS-CoV-2 Pandemic on the Management of Patients with Hepatocellular Carcinoma

Worldwide, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) significantly increases mortality and morbidity. The Coronavirus Disease 2019 (COVID-19) outbreak has had a considerable impact on healthcare systems all around the world, having a significant effect on planned patient activ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guarino, Maria, Cossiga, Valentina, Capasso, Mario, Mazzarelli, Chiara, Pelizzaro, Filippo, Sacco, Rodolfo, Russo, Francesco Paolo, Vitale, Alessandro, Trevisani, Franco, Cabibbo, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369221/ https://www.ncbi.nlm.nih.gov/pubmed/35956091 http://dx.doi.org/10.3390/jcm11154475

Ejemplares similares

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance
por: Pelizzaro, Filippo, et al.
Publicado: (2023)

Liquid Biopsy in Hepatocellular Carcinoma: Where Are We Now?
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Relevance of Bile Acids in Cholangiocarcinoma Pathogenesis: Critical Revision and Future Directions
por: Cossiga, Valentina, et al.
Publicado: (2023)

Safety and Immunogenicity of Anti-SARS-CoV-2 Booster Dose in Patients with Chronic Liver Disease
por: Cossiga, Valentina, et al.
Publicado: (2023)

Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors and Applicability of First-Line Atezolizumab/Bevacizumab in a Real-Life Setting
por: Plaz Torres, Maria Corina, et al.
Publicado: (2021)

Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies
por: Pinto, Elisa, et al.
Publicado: (2023)

Overview of Prognostic Systems for Hepatocellular Carcinoma and ITA.LI.CA External Validation of MESH and CNLC Classifications
por: Vitale, Alessandro, et al.
Publicado: (2021)

Surveillance as Determinant of Long-Term Survival in Non-Transplanted Hepatocellular Carcinoma Patients
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Effectiveness of SARS-CoV-2 vaccination in liver transplanted patients: The debate is open!
por: Guarino, Maria, et al.
Publicado: (2022)

Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
por: Pelizzaro, Filippo, et al.
Publicado: (2022)

Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
por: Giannini, Edoardo G., et al.
Publicado: (2019)

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
por: Marasco, Giovanni, et al.
Publicado: (2021)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma
por: Farinati, Fabio, et al.
Publicado: (2016)

Transarterial radioembolization for hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2016)

Humoral Response to 2-dose BNT162b2 mRNA COVID-19 Vaccination in Liver Transplant Recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: a pilot case–control study
por: Morisco, Filomena, et al.
Publicado: (2018)

Circulating MicroRNA-21 and MicroRNA-122 as Prognostic Biomarkers in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization
por: Pelizzaro, Filippo, et al.
Publicado: (2021)

Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2017)

Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib
por: Sansone, Vito, et al.
Publicado: (2021)

Update on new approaches in the management of hepatocellular carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2010)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Risk of SARS-CoV-2 contagion in otolaryngology specialists
por: Ralli, Massimo, et al.
Publicado: (2022)

Use of Telemedicine for Chronic Liver Disease at a Single Care Center During the COVID-19 Pandemic: Prospective Observational Study
por: Guarino, Maria, et al.
Publicado: (2020)

COVID-19 and Fatty Liver Disorders
por: Guarino, Maria, et al.
Publicado: (2023)

Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients
por: Guarino, Maria, et al.
Publicado: (2022)

Genetic Analysis of the Coronavirus SARS-CoV-2 Host Protease TMPRSS2 in Different Populations
por: Russo, Roberta, et al.
Publicado: (2020)

Prognostic scores for hepatocellular carcinoma: none is the winner
por: Cammà, Calogero, et al.
Publicado: (2009)

Estimating asymptomatic SARS-CoV-2 infections in a geographic area of low disease incidence
por: Caturano, Valeria, et al.
Publicado: (2021)

Hepatitis B Virus-Associated Hepatocellular Carcinoma
por: Rizzo, Giacomo Emanuele Maria, et al.
Publicado: (2022)

COVID-19 in liver transplant recipients: incidence, hospitalization and outcome in an Italian prospective double-centre study
por: Guarino, Maria, et al.
Publicado: (2022)

Svizzera e Italia, per sette secoli: in occasione del settecentesimo anniversario della fondazione della confederazione elvetica
por: Cossiga, Francesco
Publicado: (1991)

Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
por: Tovoli, Francesco, et al.
Publicado: (2020)

Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs
por: Reggidori, Nicola, et al.
Publicado: (2023)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study
por: Cossiga, Valentina, et al.
Publicado: (2022)

Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma
por: De Lorenzo, Stefania, et al.
Publicado: (2022)

Refractory celiac disease and its mimickers: a review on pathogenesis, clinical-pathological features and therapeutic challenges
por: Scarmozzino, Federico, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3e850fpo280dqh0ad0irid4cfa